Active Components Formulation Developed from Fuzheng Huayu Recipe for Anti-Liver Fibrosis
Chinese Journal of Integrative Medicine2022年28卷第6期 页码:538-544
Affiliations:
1.Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai(201203), China
2.Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai (201203), China
Author bio:
Prof. LIU Cheng-hai, E-mail: chenghailiu@hotmail.com
Funds:
Ministry of Science and Technology of the People's Republic of China(2014ZX10005001);the National Natural Science Foundation of China(81603467;81730109);the Third Batch of Open Projects of Shanghai Innovation Center of Traditional Chinese Medicine Health Service(ZYJKFW201811013)
Xin SUN, Ye TAN, Jing LYU, 等. 扶正化瘀方抗肝纤维化活性成分的配伍研究[J]. Chinese Journal of Integrative Medicine, 2022,28(6):538-544.
Xin SUN, Ye TAN, Jing LYU, et al. Active Components Formulation Developed from Fuzheng Huayu Recipe for Anti-Liver Fibrosis[J]. Chinese Journal of Integrative Medicine, 2022,28(6):538-544.
Xin SUN, Ye TAN, Jing LYU, 等. 扶正化瘀方抗肝纤维化活性成分的配伍研究[J]. Chinese Journal of Integrative Medicine, 2022,28(6):538-544. DOI: 10.1007/s11655-021-3293-x.
Xin SUN, Ye TAN, Jing LYU, et al. Active Components Formulation Developed from Fuzheng Huayu Recipe for Anti-Liver Fibrosis[J]. Chinese Journal of Integrative Medicine, 2022,28(6):538-544. DOI: 10.1007/s11655-021-3293-x.
To screen the active components from Fuzheng Huayu Recipe (FZHY) and redesign a new recipe composed of the active components
and validate the effect of active components formulation from FZHY against liver fibrosis.
Methods:
2
Thirty-two components from FZHY were evaluated for their activities against liver fibrosis respectively
with 6 kinds of cell models
in vitro
including oxidative stressed hepatocyte in L-02
hypoxia injured/proliferative hepatic sinusoidal endothelial cells in SK-HEP-1 and human hepatic sinusoidal endothelial cells (HHSEC)
and activated hepatic stellate cell in LX-2. The comprehensive activity of each component against liver fibrosis was scored according to the role of original herbs in FZHY and cell functions in fibrogenesis. Totally 7 active components were selected and combined with equal proportion to form a novel active components formulation (ACF). The efficacy of ACF on liver fibrosis were evaluated on activation of LX-2 and proliferation of HHSEC
in vitro
and in liver fibrosis model mice induced by dimethylnitrosamine (DMN). Totally 72 mice were divided into 6 groups using a random number table
including normal
high-dose ACF control (20 μmol/L×7 components/kg body weight)
model
low-
medium-
high-dose ACF groups (5
10
20 μmol/L×7 components/kg body weight
respectively). Hematoxylin eosin and Sirius red stainings were used to observe inflammation and fibrosis change of liver tissue; scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were utilized to observe the effect of ACF on ultrastructure of hepatic sinusoids.
Results:
2
Fifteen components from FZHY showed higher scores for their activity on against liver fibrosis. Among them
7 components including tanshinone ⅡA
salvianolic acid B
cordycepin
amygdalin
quercetin
protopanaxatriol
and schizandrin B were recombined with equal proportions to form ACF. ACF at 1
2
4 μmol/L showed strong inhibitory effects on activation of LX-2 and proliferation of HHSEC
in vitro
(all
P
<
0.01). Compared with the model group
ACF attenuated liver collagen deposition
improved sinusoidal capillarization in a dose-dependent manner (all
P
<
0.05).
Conclusions:
2
ACF exerts a satisfactory effect against experimental liver fibrosis and attenuates sinusoidal capillarization
which warrant a further research and development for herbal components formulation on liver fibrosis.
Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010;53:976-980.
Friedman Scott L. Hepatic fibrosis: emerging therapies. Dig Dis 2015;33:504-507.
Lee Youngmin A, Wallace Michael C, Friedman Scott L.Pathobiology of liver fibrosis: a translational success story.Gut 2015;64:830-841.
Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, et al.Multicenter clinical study on Fuzhenghuayu Capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005;11:2892-2899.
Hassanein T, Box TD, Tong MJ, Pozza R, Rossaro L, Glenn JS, et al. A phase Ⅱ, randomized, placebo-controlled,double-blind, multicenter study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis. Hepatol Int 2014;8:S308-S309.
Liu CH, Hu YY, Xu LM, Liu C, Liu P. Effect of Fuzheng Huayu Formula and its actions against liver fibrosis. Chin Med 2009;4:38-53.
Liu HL, Lv J, Zhao ZM, Xiong AM, Tan Y, Glenn Jeffrey S,et al. Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis. Sci Rep 2019;9:18719.
Zhao ZM, Liu HL, Sun X, Guo T, Shen L, Tao YY, et al.Levistilide A inhibits angiogenesis in liver fibrosis via vascular endothelial growth factor signaling pathway. Exp Bio Med 2017;242:974-985.
Lv J, Tan Y, Zhao ZM, Huang K, Shen L, Tao YY, et al.Fuzheng Huayu components formula exerted anti-liver fibrosis through inhibiting angiogenesis. World Chin Med(Chin) 2015;10:186-191.
Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981;112:70-75.
Friedman Scott L. Evolving challenges in hepatic fibrosis.Nat Rev Gastroenterol Hepatol 2010;7:425-436.
Liu CH, Zhao ZM, Lv J. Advances in the understanding and treatment of liver fibrosis in traditional Chinese medicine. J Clin Hepatol (Chin) 2019;35:728-733.
Cui XW, Zhang GJ. Component Chinese medicine and Chinese medicine modernization. Lishizhen Med Mater Med Res (Chin) 2009;20:1290-1291.
Zhang BL, Wang YY. Basic research on key scientific issues of TCM prescription-modern Chinese medicine was developed by the combination of components. Chin J Nat Med (Chin) 2005;3:258-261.
Huang K, Zhao ZM, Liu HL, Sun X, Lv J, Tao YY, et al.Evaluation of cryptotanshinone inhibition of angiogenesis in human hepatic sinusoidal endothelial cells. Acta Pharmaceut Sin (Chin) 2016;51:1257-1262.
Zhu CW, Lv J, Zhao ZM, Tao YY, Liu CH. Effect of schisantherin A inhibit liver sinusoid endothelial cell function and action against liver fibrosis relating to angiogenesis.China J Tradit Chin Med Pharm (Chin) 2016;41:279-284.
Guo T, Liu ZL, Zhao Q, Zhao ZM, Liu CH. A combination of astragaloside Ⅰ, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo. Acta Pharmacol Sin 2018;39:1483-1492.
Xu MM, Wang XH, Zou Y, Zhong XS. Key role of liver sinusoidal endothelial cells in liver fibrosis. Biosci Trends 2017;11:163-168.
Greuter T, Shah VH. Hepatic sinusoids in liver injury,inflammation, and fibrosis: new pathophysiological insights.J Gastroenterol 2016;51:511-519.